Lovastatin and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Lovastatin (lovastatin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lisinopril, and have Breast cancer.

The phase IV clinical study analyzes which people have Hearing loss when taking Lovastatin. It is created by eHealthMe based on reports of 31,864 people who have side effects when taking Lovastatin from the FDA, and is updated regularly.

What is Lovastatin?

Lovastatin has active ingredients of lovastatin. It is often used in high blood cholesterol. eHealthMe is studying from 33,048 Lovastatin users. Check the latest studies of Lovastatin.

What is Hearing loss?

Hearing loss is found to be associated with 1,357 drugs and 2,387 conditions by eHealthMe. Check the latest studies of Hearing loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 31, 2026

31,864 people reported to have side effects when taking Lovastatin.
Among them, 85 people (0.27%) have Hearing loss.

Among these 85 people:

How long have people been on Lovastatin when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Lovastatin? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Hearing loss when taking Lovastatin? *

What are other drugs people take besides Lovastatin? *

What are other side effects people have besides Hearing loss? *

Pain: 28 people, 32.94%
Joint Pain: 25 people, 29.41%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 24 people, 28.24%
Stress And Anxiety: 23 people, 27.06%
Osteonecrosis Of Jaw (death of bone of jaw): 22 people, 25.88%
Decreased Interest: 22 people, 25.88%
Rashes (redness): 21 people, 24.71%
Depression: 20 people, 23.53%
Gait Disturbance: 20 people, 23.53%
Fatigue (feeling of tiredness): 20 people, 23.53%

What are the existing conditions these people have? *

Breast Cancer: 10 people, 11.76%
Cardiac Failure: 8 people, 9.41%
Multiple Myeloma (cancer of the plasma cells): 7 people, 8.24%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 5.88%
Diabetes: 5 people, 5.88%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 5.88%
Blood Pressure Abnormal: 4 people, 4.71%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 3.53%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 3.53%
Cardiac Disorder: 3 people, 3.53%

* Approximation only. Some reports may have incomplete information.

Do you take Lovastatin and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lovastatin:

Lovastatin (33,048 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Lovastatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,357 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,387 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lovastatin (the active ingredients of Lovastatin) and Lovastatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.